Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting

Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced it will present data from the SB101 multiple-dose clinical trial of SON-1010 (IL12-FHAB) at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The presentation, titled "Clinical development of a novel form of interleukin-12 with extended pharmacokinetics," is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM. SON-1010 is designed for treating adult patients with advanced solid tumors and utilizes F_HAB technology for improved targeting of tumor and lymphatic tissues. This marks a significant step in Sonnet's commitment to advancing oncology treatments.

Positive

• Presentation of clinical trial data at a major cancer research event, potentially increasing visibility and credibility.
• Use of innovative F_HAB technology for targeted treatment, indicating potential for improved efficacy and safety.

Negative

• None.

PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored SB101 multiple-dose clinical trial (NCT05352750) of SON-1010 (IL12-F_HAB) in adult patients with advanced solid tumors will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, Florida.

Presentation details:

Title: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Presentation Type: Poster
Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM
Abstract Number: CT245
Location: Poster Section 46

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. Known as F_HAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's F_HAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F_HAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet BioTherapeutics Investor Contact:

Michael V. Morabito, Ph.D.
Solebury Strategic Communications
917-936-8430
mmorabito@soleburystrat.com

SOURCE: Sonnet BioTherapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/743738/Sonnet-BioTherapeutics-to-Present-Clinical-Data-from-the-SB101-Study-with-SON-1010-at-the-AACR-2023-Annual-Meeting

FAQ

What data will Sonnet BioTherapeutics present at the AACR Annual Meeting 2023?

Sonnet will present data from the SB101 clinical trial of SON-1010 (IL12-FHAB), focusing on its development for advanced solid tumors.

When is Sonnet BioTherapeutics' presentation at the AACR Annual Meeting?

The presentation is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM.

What is SON-1010 and its purpose?

SON-1010 is a biologic drug designed to treat adult patients with advanced solid tumors using innovative targeting technology.

What is F_HAB technology used by Sonnet BioTherapeutics?

F_HAB technology utilizes a fully human single chain antibody fragment for targeted delivery of treatments to tumor and lymphatic tissues.

How does the SB101 trial impact Sonnet BioTherapeutics' market position?

Positive trial data could enhance Sonnet's market position by showcasing the efficacy of its innovative therapies in oncology.